HomeCompareSTGYF vs JNJ

STGYF vs JNJ: Dividend Comparison 2026

STGYF yields 1.79% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 JNJ wins by $6.7K in total portfolio value· pulled ahead in Year 8
10 years
STGYF
STGYF
● Live price
1.79%
Share price
$12.39
Annual div
$0.22
5Y div CAGR
7.5%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$23.6K
Annual income
$434.76
Full STGYF calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — STGYF vs JNJ

📍 JNJ pulled ahead of the other in Year 8

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSTGYFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, STGYF + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
STGYF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

STGYF
Annual income on $10K today (after 15% tax)
$152.25/yr
After 10yr DRIP, annual income (after tax)
$369.55/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, JNJ beats the other by $3,616.44/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of STGYF + JNJ for your $10,000?

STGYF: 50%JNJ: 50%
100% JNJ50/50100% STGYF
Portfolio after 10yr
$26.9K
Annual income
$2,562.08/yr
Blended yield
9.51%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

STGYF
Analyst Ratings
2
Buy
Consensus: Buy
Altman Z
1.3
Piotroski
7/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

STGYF buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSTGYFJNJ
Forward yield1.79%2.13%
Annual dividend / share$0.22$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR7.5%28%
Portfolio after 10y$23.6K$30.3K
Annual income after 10y$434.76$4,689.40
Total dividends collected$3.0K$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: STGYF vs JNJ ($10,000, DRIP)

YearSTGYF PortfolioSTGYF Income/yrJNJ PortfolioJNJ Income/yrGap
1$10,893$192.55$10,592$272.30+$301.00STGYF
2$11,866$210.72$11,289$357.73+$577.00STGYF
3$12,927$230.62$12,123$472.89+$804.00STGYF
4$14,084$252.42$13,141$629.86+$943.00STGYF
5$15,346$276.30$14,408$846.81+$938.00STGYF
6$16,723$302.47$16,021$1,151.60+$702.00STGYF
7$18,225$331.15$18,122$1,588.22+$103.00STGYF
8← crossover$19,863$362.57$20,930$2,228.20$1.1KJNJ
9$21,651$397.01$24,792$3,191.91$3.1KJNJ
10$23,601$434.76$30,274$4,689.40$6.7KJNJ

STGYF vs JNJ: Complete Analysis 2026

STGYFStock

Stingray Group Inc. operates as a music, media, and technology company worldwide. The company offers Stingray Music, a multiplatform music service that gives listeners free access to curated music channels on television (TV), web, and mobile; Stingray Naturescape, a channel in 4K resolution; Stingray Now 4K, a curated 4K TV channel; and Stingray Festival 4K, a television channel that broadcasts exclusively in native 4K and Dolby Digital audio. It also provides Stingray Qello, an over-the-top streaming service on TV, mobile, and the web; Stingray Classica, a TV channel dedicated to classical music, including operas, ballets, concerts, and documentaries; Stingray iConcerts, a source for various live concerts; and Stingray DJAZZ, a TV channel dedicated to jazz and jazz-related genres, such as soul, blues, funk, gospel, hip-hop, fusion, reggae, Latin, swing, and bebop. In addition, the company offers karaoke services comprising The Voice, Yokee Piano, Yokee Karaoke, Yokee Guitar, Piano Academy, The Piano Keyboard, Stingray Kids' Karaoke, and Yokee Music, as well as Stingray Karaoke, a video on demand and TV app. Further, it provides music videos TV channels that include Stingray Country, Stingray cmusic, PalmarèsADISQ par Stingray, Stingray Hits!, Stingray Vibe, Stingray Loud, Stingray Retro, Stingray LiteTV, and Stingray Juicebox; and operates approximately 100 radio stations across Canada, as well as offers advertising solutions. The company distributes its products and services through various platforms that include digital cable TV, satellite TV, IPTV, OTT, the internet, mobile devices, game consoles, and connected cars. It serves cable and telecom companies, retailers, small and medium businesses, and directly to consumers. The company was formerly known as Stingray Digital Group Inc. and changed its name to Stingray Group Inc. in December 2018. Stingray Group Inc. was founded in 2007 and is headquartered in Montreal, Canada.

Full STGYF Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this STGYF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

STGYF vs SCHDSTGYF vs JEPISTGYF vs OSTGYF vs KOSTGYF vs MAINSTGYF vs ABBVSTGYF vs MRKSTGYF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.